Drugs / SMS001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06693336 | Nov 2024 → Nov 2026 expected | non-small cell lung carcinoma | ToLymph Inc. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SMS001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06693336 ↗ |